US FDA Approves New Label Update for CAR T-Cell Therapy Yescarta^® Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome

Kite announced the FDA approved an update to the prescribing information for Yescarta® to include use of prophylactic corticosteroids across all approved indications.